#### 1 TITLE:

- Isolation and Characterization of Human Adipocyte-derived Extracellular Vesicles Using
   Filtration and Ultracentrifugation
- 4

### 5 **AUTHORS AND AFFILIATIONS:**

- 6 Naveed Akbar<sup>1</sup>, Katherine E. Pinnick<sup>2</sup>, Daan Paget<sup>1</sup>, Robin P. Choudhury<sup>1</sup>
- 7
- <sup>1</sup>Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford,
   Oxford, UK
- 10 <sup>2</sup> Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
- 11
- 12 Corresponding Author
- 13 Naveed Akbar Naveed.Akbar@cardiov.ox.ac.uk
- 14
- 15 E-mail Addresses of Co-authors
- 16 Katherine Pinnick katherine.pinnick@ocdem.ox.ac.uk
- 17 Daan Paget daan.paget@lmh.ox.ac.uk
- 18 Robin P. Choudhury robin.choudhury@cardiov.ox.ac.uk
- 19

## 20 **KEYWORDS**:

- 21 Adipose, Exosomes, Microvesicles, Characterization, Signaling.
- 22

# 23 SUMMARY:

We describe the isolation of human adipocyte-derived extracellular vesicles (EVs) from gluteal and abdominal adipose tissue using filtration and ultracentrifugation. We characterize the isolated adipocyte-derived EVs by determining their size and concentration by Nanoparticle Tracking Analysis and by western blotting for the presence of EV-protein tumor susceptibility gene 101 (TSG101).

29

# 30 ABSTRACT:

31 Extracellular vesicles (EVs) are lipid enclosed envelopes that carry biologically active material 32 such as proteins, RNA, metabolites and lipids. EVs can modulate the cellular status of other cells 33 locally in tissue microenvironments or through liberation into peripheral blood. Adipocyte-34 derived EVs are elevated in the peripheral blood and show alterations in their cargo (RNA and 35 protein) during metabolic disturbances including, obesity and diabetes. Adipocyte-derived EVs 36 can regulate the cellular status of neighboring vascular cells, such as endothelial cells and 37 adipose tissue resident macrophages to promote adipose tissue inflammation. Investigating 38 alterations in adipocyte-derived EVs in vivo is complex because EVs derived from peripheral 39 blood are highly heterogenous and contain EVs from other sources, namely platelets, 40 endothelial cells, erythrocytes and muscle. Therefore, the culture of human adjpocytes provides 41 a model system for the study of adipocyte derived EVs. Here, we provide a detailed protocol for 42 the extraction of total small EVs from cell culture media of human gluteal and abdominal 43 adipocytes using filtration and ultracentrifugation. We further demonstrate the use of Nanoparticle Tracking Analysis (NTA) for quantification of EV size and concentration and show 44

the presence of EV-protein tumor susceptibility gene 101 (TSG101) in the gluteal and abdominal
 adipocyte derived-EVs. Isolated EVs from this protocol can be used for downstream analysis
 including, transmission electron microscopy, proteomics, metabolomics, small RNA-sequencing,

48 microarray and utilized in functional in vitro/in vivo studies.

49

### 50 **INTRODUCTION:**

51 Extracellular vesicles (EVs) are lipid enclosed envelopes that carry biologically active material such as proteins, microRNAs, metabolites and lipids. The term EVs denotes various 52 subpopulations, which include exosomes, microvesicles (microparticles/ectosomes) and 53 apoptotic bodies<sup>1</sup>. EVs may serve as biomarkers because they are implicated in pathological 54 55 signaling and released into bio fluids including blood and urine. EVs can modulate the cellular status of other cells locally in tissue microenvironments or through liberation into peripheral 56 57 blood<sup>2</sup>. EVs bear features of their parent cell but differentiation of each sub population is primarily based on EVs size and protein content such as EVs markers, including the presence of 58 59 tetraspanins (CD9, CD63 and CD81), tumor susceptibility gene 101 (TSG101) and ALG-2-60 interacting protein X (ALIX). These protein markers are representative of the endosomal origin (CD9, CD63 and CD81) for exosomes, which are generated inside multi-vesicular bodies or 61 represent proteins associated with budding or blebbing directly from the plasma membrane for 62 63 microvesicles. However, there is a significant overlap between these subpopulations and it is 64 difficult to distinguish individual sub-populations in complex bio fluids such as plasma, serum or 65 urine.

66

67 Metabolic disturbances, including obesity, insulin resistance, and perturbations in extracellular 68 glucose, oxygen and inflammation can alter the size and concentration of EVs and their cargo. 69 Adipocyte-derived EVs carry Perilipin A, adiponectin and show alterations in their protein and RNA cargo during obesity and diabetes<sup>3-6</sup>. Adipocyte-derived EVs regulate the cellular status of 70 neighboring vascular endothelial cells<sup>7</sup> and adipose tissue resident macrophages to promote 71 adipose tissue inflammation and insulin resistance<sup>8-11</sup>. Investigating alterations in adipocyte-72 derived EVs in vivo is complex because EV populations derived from complex biofluids such as 73 74 plasma, serum or urine contain EVs from multiple sources, such as platelets, endothelial cells, 75 erythrocytes and muscle, which are implicated in the pathogenesis of metabolic dysfunction 76 and disease.

77

78 The culture and in vitro differentiation of human preadipocytes, therefore, provides a model 79 system for the study of adjpocyte derived EVs. Here, we provide a detailed protocol for the 80 extraction of total small EVs from cell culture media of human adipocytes using syringe filtration and ultracentrifugation. Ultracentrifugation remains a popular method of isolation for 81 82 EVs because it is easily accessible and requires little prior specialist knowledge. However, other methods such as precipitation, size exclusion chromatography and immunoaffinity capture 83 84 using tetraspanins enable EV isolation from a range of biofluids including plasma, serum, urine 85 and conditioned cell culture media. Each method, including the ultracentrifugation protocol described here produce EV preparations of varying purity because the methods can co-isolate 86 87 soluble proteins and lipoproteins, which may mask as EVs. Combining this ultrancentrifugation 88 protocol with other methods such as density centrifugation, size, exclusion chromatography

89 and immune-affinity capture dramatically increases the purity of isolated EVs. But similar to 90 ultracentrifugation, these other methods do not allow the capture of independent sub-91 populations of EVs from complex samples such as blood, plasma and urine. Therefore, cultures of selected cell populations remain one of the most robust methods for generating high yields 92 93 of cell specific EVs. Each EV method has a number of caveats and the choice of method can 94 impact the types of EVs isolated and their concentrations, which may bias downstream 95 mechanistic investigations into cellular and tissue signaling and determination of EV-cargo for diagnostic studies; these methodological issues of EV isolation are discussed elsewhere and in 96 the limitation section below<sup>4,12</sup>. Here, we describe the isolation of human adipocyte derived EVs 97 using filtration and ultracentrifugation. We further demonstrate the use of Nanoparticle 98 99 Tracking Analysis (NTA) for quantification of EV size and concentration and show the presence of EV-protein tumor susceptibility gene 101 (TSG101) in our human adjpocyte derived EVs. 100 101 Isolated EVs from this protocol can be used for downstream analysis, including transmission 102 electron microscopy, proteomics, metabolomics, small RNA-sequencing, microarray and utilized 103 in functional in vitro/in vivo studies.

104

105 **PROTOCOL:** 106 107 All methods were approved by the institutional ethics review board at the University of Oxford. 108 Adipose tissue was obtained by needle biopsy under local anesthetic from healthy volunteers. 109 110 1. Preparation of cell culture medium and buffers 111 112 Prepare a collagenase digestion buffer by dissolving collagenase H (1 mg/mL) in Hanks 1.1. 113 Balanced Salt Solution (HBSS) (without calcium chloride and without magnesium chloride) and 114 sterile filter using a 0.2  $\mu$ m pore syringe filter. 115 116 **1.1.1.** Prepare the collagenase digestion buffer no more than 10 minutes before use. 117 118 1.2. Prepare growth medium (GM) as follows: Dulbecco's Modified Eagle's Medium/Ham's 119 nutrient mixture F12 (DMEM/F12) supplemented with 10% fetal bovine serum (FBS), 100 120 units/mL penicillin, 100 µg/mL streptomycin, 2 mM L-glutamine and 0.5 ng/mL fibroblast 121 growth factor (FGF). 122 123 Prepare the basic differentiation medium (basic DM) as follows: DMEM/F12 1.3. 124 supplemented with 100 units/mL penicillin, 100  $\mu$ g/mL streptomycin, 2 mM L-glutamine, 17  $\mu$ M 125 pantothenate, 100 nM human insulin, 10 nM triiodo-L-thyronine, 33 µM biotin, 10 µg/mL 126 transferrin and 1 µM dexamethasone. 127 128 Prepare complete differentiation medium (complete DM) by supplementing the basic 1.4. 129 DM from step 1.3 with 0.25 mM 3-isobuty-1-methylxanthine and 4  $\mu$ M troglitazone. 130 131 1.5. Prepare 10 mM fatty acid stock solutions complexed to 10% essentially fatty acid free 132 bovine serum albumin (BSA) as follows. 133 134 1.5.1. Dissolve 16 g of BSA in 160 mL of DMEM/F12 medium and warm to 37 °C. In three 135 separate 50 mL conical tubes, weigh out 150 mg of sodium oleate, 139 mg of sodium palmitate and 151 mg of sodium linoleate. Add 50 mL of the warmed BSA solution to each tube and mix 136 137 well by repeated vortexing. 138 139 1.5.2. Return the oleate and linoleate tubes to the 37 °C water bath for 15 minutes. Mix by 140 vortexing until completely dissolved. 141 142 1.5.3. For the palmitate solution place the tube in a 65 °C water bath for 2-3 minutes. Mix 143 vigorously by vortexing. 144 145 1.5.4. Repeat step 1.5.3. until fully dissolved – approximately 30 minutes. 146 147 NOTE: Some small particles may still be visible. 148

149	1.5.5.	Sterile filter the fatty acid solutions using a 0.2 $\mu$ m pore syringe filter.		
150				
151	1.5.6.	Confirm the non-esterified fatty acids concentration of each stock solution using an		
152	approp	appropriate assay.		
153				
154	NOTE:	Fatty acid stocks should be 10 mM (± 10%) to give a molar ratio of 6:1 between fatty acid		
155	and B	A. If the concentration is outside this range the stock solution should be remade. Stock		
156	solutio	ins can be allquoted and stored at -30 °C.		
157	2			
158	Ζ.	Digestion of numan adipose tissue biopsies		
159	2 1	Claudy studie the contents of the bigger symptom through a 200 year starily call studies		
160	Z. I.	Slowly strain the contents of the blopsy syringe through a 200 $\mu$ m sterile cell strainer		
161	attach	ed to a 50 mL conical tube so that the adipose tissue is collected in the strainer.		
162	2 2	Transfer the strainer to a new 50 mL conical tube and wash the adjunce tissue three		
164	z.z.	with 10 mL of HRSS		
165	times			
166	ΝΟΤΕ·	It may be necessary to remove blood clots and fibrous tissue with surgical scissors or to		
167	reneat	the HBSS wash to remove excess red blood cells		
168	repeat			
169	23	Weigh the washed tissue		
170	2.01			
171	NOTE:	We typically obtain 400-800 mg of tissue by needle biopsy.		
172				
173	2.4.	Put the collagenase digestion buffer in a sterile 50 mL conical tube and add the washed		
174	tissue.	Surgical scissors can be used at this step to mince the tissue into equal sized pieces.		
175				
176	NOTE:	Use 5 mL of buffer per 0.5 g tissue. For larger tissue, samples can be minced in a Petri		
177	dish.			
178				
179	2.5.	Place the tube into a 37 °C shaking water bath and incubate for 35 - 40 minutes.		
180				
181	NOTE:	Following successful digestion the solution should appear milky. If small pieces of tissue		
182	are sti	ll visible shake by hand for a further 10 - 20 s.		
183				
184	3.	Isolation of preadipocytes		
185				
186	3.1.	To pellet the preadipocyte fraction centrifuge at 1000 x <i>g</i> for 5 minutes.		
187				
188	3.2.	Aspirate and discard the floating adipocyte layer and supernatant leaving approximately		
189	1 mL o	f HBSS covering the cell pellet.		
190				

191 3.3. Resuspend the pellet in 5 mL of HBSS and pass the cell suspension through a 250  $\mu$ m 192 pore size mesh followed by a 100  $\mu$ m mesh to remove any undigested material. Collect the cell 193 suspension in a 15 mL conical tube.

194

196

195 3.4. Centrifuge at 1000 x g for 5 minutes.

197 NOTE: After this step, the preadipocyte fraction can be treated with a red blood cell lysis198 solution if red blood cell contamination is an issue.

199 200

201

3.5. Aspirate and discard the supernatant.

202 3.6. Resuspend the cell pellet in 5 mL of GM (step 1.2) and seed into a 25 cm<sup>2</sup> adherent 203 tissue culture flask. Place the flask in a cell culture incubator (5%  $CO_2$ , 37 °C).

204

206

208

210

213

- 205 4. Maintenance of preadipocyte cultures
- 207 4.1. Replace the GM every 2 days while the cells are proliferating
- 209 NOTE: Cell proliferation rates may vary between donors.
- 4.1.1. When the cells reach approximately 80% confluence transfer them to a 75 cm<sup>2</sup> adherent
   tissue culture flask. Remove the GM and wash the cells with phosphate buffered saline (PBS).
- 4.1.2. Discard the PBS and add 0.5 mL of highly purified cell dissociation enzymes to
  disassociate the attached cells. Incubate at 37 °C for 5 minutes.
- 216

4.1.3. Tap the flask sharply to release the cells and add 5 mL of GM. Collect the cell suspensionin a 15 mL conical tube.

219

221

220 4.2. Centrifuge at 1000 x g for 5 minutes

4.3. Aspirate and discard the supernatant. Resuspend the cell pellet in 5 mL of GM and transfer to a 75 cm<sup>2</sup> flask. Top up the GM to a final volume of 12 mL and replace the flask in the cell culture incubator (5% CO<sub>2</sub>, 37 °C).

225

NOTE: To maintain the cells continue to change the GM every 2-3 days. When the cells reach 80% confluence repeat steps 4.2-4.3 and divide the cells 1:3 into new 75 cm<sup>2</sup> flasks. This can be repeated for several passages until sufficient number of cells have been generated for the experimental set up. We would not recommend more than 10 passages as proliferation and differentiation capacity of these preadipocytes declines.

- 231
- 232 5. Seeding preadipocytes for adipogenic differentiation
- 233

Count the cells using a hemocytometer and seed 200,000 cells into multiple wells of a 6 234 5.1. well plate in 2 mL of GM. Alternatively seed 3.5 million cells per T175 cm<sup>2</sup> flask in 22 mL of GM 235 236 media. 237 238 Allow the cells to proliferate for a further 2--4 days until they reach full confluence, 5.2. 239 changing the GM on the second day of culture. 240 241 To begin adjpogenic differentiation remove the GM and replace with complete DM for 4 5.3. days (2 mL of complete DM per well of a 6 well plate or 22 mL for a T175 cm<sup>2</sup> flask. 242 243 244 NOTE: Replace with fresh complete DM on day 2. 245 246 On day 4 remove the complete DM and replace with 2 mL basic DM supplemented with 5.4. 22.5  $\mu$ M oleate, 15  $\mu$ M palmitate and 12.5  $\mu$ M linoleate to give a total fatty acid concentration 247 of 50  $\mu$ M per well of a 6 well plate or 22 mL for a T175 cm<sup>2</sup> flask. Replace with media every 2 248 249 days for a further 10 days. 250 251 NOTE: From day 7 onwards lipid droplets should be visible in the differentiating preadipocytes. 252 253 5.5. On culture day 14 collect the media from the cells for isolation of adipocyte-derived EVs 254 255 Preparation of cell culture supernatant for extracellular vesicle isolation or storage **6**. 256 and future extracellular vesicle isolation 257 Remove cell culture supernatants from each 6 well plate and combine. Add to a 15 mL 258 6.1. tube or remove all the cell culture supernatant from a T175 cm<sup>2</sup> flask and add to a 50 mL tube. 259 260 Centrifuge for 10 minutes are 4 °C at 1000 x q. 261 6.2. 262 263 <mark>6.3.</mark> Decant supernatant in to a new clean 15 mL or 50 mL tube by pouring, respectively. 264 265 Remove the barrel of a 10 mL syringe and attach 0.45 µm syringe filter. <mark>6.4.</mark> 266 267 6.5. Pour in the supernatant to the syringe reservoir and apply gentle pressure at the syringe barrel opening with a thumb or palm until the cell culture supernatant freely passes through 268 269 the filter. 270 271 NOTE: The speed of this filtration step can vary depending on the type of syringe filter. 272 6.6. Collect the filtrate in a clean 50 mL tube. 273 274 275 NOTE: If required the conditioned filtered media can be stored at this point at -80 °C for several weeks. When required defrost the cell culture supernatants at 4 °C and centrifuge for 10 276 277 minutes are 4 °C at 1000 x g. Decant supernatant into a clean tube by pouring before

278	contin	uing with the EV isolations.
2/9	<u> </u>	Callect the filtrate in a clean EQ rol tube
280	0.7.	
282	7.	Isolation of extracellular vesicles
283		
284	7.1.	Label a 13 mL ultracentrifugation tube by drawing a circle at the bottom of the tube,
285	where	the expected EV pellet will form and mark a line around the neck of the tube for
286	<mark>orient</mark> a	ition in the ultracentrifugation tube rotor. Label the tube with a sample identifier.
287	_	
288	<mark>7.2.</mark>	Place tube in tube holder.
289		
290	<mark>7.3.</mark>	Attach a 16G needle to a 10 mL syringe, and remove the syringe barrel.
291		
292	<mark>7.4</mark> .	Remove the protective cover from needle and insert the needle into the neck of the
293	ultrace	intrifugation tube.
294	75	Pour call culture superpatent directly into the syringe barrol to fill the
295	v.J.	ntrifugation tube
290		
200	<b>7</b> C	Top up the tube with PPS as persons uptil full
290	<mark>7.0.</mark>	Top up the tube with PBS as necessary until full.
299		Allow the tube to clightly everflow if necessary, ensuring there are no air spaces in the
201	NOTE.	ntrifugation tube and no air hubbles
202		inclugation tube and no all bubbles
202	<mark>7 7</mark>	Soal ultracentrifugation tube using a coldiering iron, ensuring the tube is airtight by
204	/./.	sear diffacenting ation tube using a solutering non, ensuring the tube is antight by
304	squeez	ing the tube gently.
306	78	Place the ultracentrifugation tubes in the ultracentrifugation rotor, ensure the line
307	marke	d at the top of the tube and the circle drawn at the base of the tube are facing outwards
308	where	the FV nellet will form
309		
310	79	Ultracentrifuge for 2 hours at 120 000 x $\alpha$ at 4 °C
311	, i și	
312	7 10	Carefully remove the rotor from the ultracentrifuge
313	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
314	7.11.	Remove ultracentrifugation tubes from the rotor and place in the tube holder.
315	· · ·	
316	7.12.	Attach a 16G needle to a 10 mL syringe.
317		
318	7.13.	Pierce the top of the ultracentrifugation tube and insert the needle 2 cm into the top of
319	the tu	be and aspirate the supernatant into the syringe.
320		
321	<mark>7.14.</mark>	Decant this EV-depleted supernatant into a 1.5 mL tube and freeze at – 80 °C.

322		
323	7.15.	Reinsert needle into the tube and carefully aspirate the remaining supernatant and
324	discard	I.
325		
326	7 16	Cut the top of the tube with a pair of scissors
327	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
328	7 17	Pour off the remaining supernatant in one quick action
329	,. <u>.</u> ,.	
330	7 18	Allow the tube to hang unside down for 1 minute
331	<b>, 10</b> .	Anow the tabe to hang applie down for I minute.
332	7 19	Pat dry any liquid that forms on the tube with paper towel
222	<mark>/.1</mark> 3.	The dry any neuronna on the tabe with paper towen.
334	7 20	Invert the tube and place in the tube holder
225	<mark>/.20.</mark>	
336	7 21	Add 100 ut of PBS to the tube
330	<mark>/ .                                   </mark>	
228	7 22	Using the tip of a night dislodge the EV pellet at the base of the tube using a
220	circula	r motion in the area marked in step 7.1
340	ch cula	Though in the area marked in step 7.1.
2/1	7 72	Vortex briefly (1.2 seconds) twice
241	<mark>7.23.</mark>	Voltex bilely (1-2 seconds), twice.
54Z 242	7 24	Jahol a new 12 mL ultracentrifugation tube by drawing a circle at the bettern of the
545 247	7.24. tubo y	table a new 15 mL diffacent nugation tube by drawing a circle at the bottom of the
344 245	cube, v	where the expected EV pellet with form and mark a fille around the fleck of tube for
545 246	onenta	ation in the ditracentifidgation tube rotor. Laber tube with sample identifier.
540 247	7 25	Place tube in tube holder
547 240	<mark>7.25.</mark>	Place tube in tube holder.
540 240		Add 12 mL DDS to a new ultracentrifugation tube using a clean suringe and needle
349	<mark>7.20.</mark>	Add 12 mL PBS to a new ditracent ingation tube using a clean syringe and needle.
550 2E1		Using a suringe and needle collect the 100 vL EV comple and add to the tube. Corefully
227	$\frac{1}{2}$	osing a synthee and needle conect the 100 dL EV sample and add to the tube. Calefully
352 353	into th	e Evs and PBS and Thise the synnige and needle by gently conecting PBS and aspirating
555 264	into th	
354 255	NOTE.	
333		Avoid creating bubbles
250		Seel ultrecontribution tube using a coldiaring iron encuring the tube is air tight bu
357 250	1.28.	sear ditracentringation tube using a soldiering iron, ensuring the tube is air tight by
358	squeez	ang the tube gently.
222 222	7.20	Place the ultracentrifugation tubes in the ultracentrifugation rates, ensure the line
30U 2C1	7.29. maarin	d at the ten of the tube and the size drawn at the base of the tube are facing a line
202	marke	u at the top of the tube and the circle drawn at the base of the tube are facing outwards.
302	7.20	Ultra contributes for 1 hours at 120,000 wast 1 <sup>9</sup> C
303 204	7.30.	Ouracentrifuge for 1 nours at 120,000 x g at 4 $^{\circ}$ C.
304	7.04	
305	<mark>7.31</mark> .	Carefully remove the rotor from the ultracentrifuge.

366		
367	7.32.	Attach a 16G needle to a 12 mL syringe.
368		
369	7.33.	Pierce the top of the ultracentrifugation tube and insert the needle 2 cm into the top of
370	<mark>the tu</mark>	be, aspirate the supernatant into the syringe and discard.
371		
372	7.34.	Cut the top of the tube with a pair of scissors.
373		
374	7.35.	Pour off the remaining supernatant in one quick action.
375		
376	7.36.	Allow the tube to hang upside down for 1 minute.
377		
378	7.37.	Pat dry any liquid that forms on the tube edge.
379		
380	<mark>7.38.</mark>	Place in the tube holder.
381		
382	<mark>7.39.</mark>	Add 100 μL PBS to the tube.
383		
384	<mark>7.40.</mark>	Using the tip of a pipette gently dislodge the EV pellet at the base of the tube using a
385	<mark>circula</mark>	r motion in the area marked in step 7.24.
386		
387	7.41.	Vortex briefly (1 - 2 seconds), twice.
388		
389	<mark>7.42.</mark>	Pipette 100 μL PBS/EV solution in to a clean 1.5 mL tube and keep on wet ice.
390		
391	NOTE:	EV are ready for downstream processing and may be frozen and stored at -80 °C.
392		
393	<mark>8.</mark>	Determination of EV size and concentration using Nanoparticle Tracking Analysis
394	<mark>(NTA)</mark>	
395		
396	<mark>8.1.</mark>	Preparing the system
397		
398	NOTE:	A detailed method for the use of Nanoparticle Tracking Analysis (NTA) for determination
399	<mark>of EV ទ</mark>	size and concentration was reported by Mehdiani <i>et al</i> . <sup>13</sup>
400		
401	<mark>8.1.1.</mark>	Defrost samples and keep them at 4 °C.
402		
403	<mark>8.1.2.</mark>	Start the NTA software by clicking the software-icon.
404		
405	<mark>8.1.3.</mark>	The software will open in 'cell check' and prompt you to fill the flow cell with deionized
406	<mark>water.</mark>	. Fill a 10 mL syringe with deionized water and push into the machine, ensuring air
407	<mark>bubbl</mark> e	es pass into the loading chamber.
408		
409	8.1.4.	Follow the on screen instructions to prepare the system through a quality check (QC).

410	
411	8.1.5. The software will perform a cell check and give you a measure of 'cell quality'. This
412	should be very good to excellent.
413	
414	8.1.6. Prepare the quality control consisting of a 100 nanometer polystyrene beads. Pipette 1
415	uL of the standard into 999 uL of dejonized water (diluted stock). Subsequently, add 10 uL of
416	the diluted stock to 2.5 mL of dejonized water (QC sample). Mix the solution by gently vortexing
417	for 2-3 seconds and by pipetting.
418	
419	NOTE: Quality control samples should be prepared freshly every day but the initial diluted stock
420	sample is stable for 1 week at 4 °C
420	
422	8.1.7 Fill a 1 mL syringe with the 1 mL of the OC sample and remove all air hubbles from the
122	svringe
425	sympe.
424	8.1.8 Inject without introducing air hubbles into the NTA sample loading chamber by gently
425	tilting the tip of the syringe into the injection chamber, whilst simultaneously pushing the
420	nlunger inject up to 950 ul of the OC sample into the chamber
427	NOTE: Do not introduce air hubbles into the cample loading chamber.
420	NOTE. Do not incloduce all bubbles into the sample loading chamber.
429	<b>9.1.0</b> The software will perform an auto alignment (feaus the compre) and will check the
450	8.1.3. The software will perform an auto angliment (locus the camera) and will check the
451 422	NOTE: If the error message (valtage too low error' the call may be wet from elegring or not
452	NOTE. If the error message voltage too low error the cell may be wet from cleaning of not
433	secure of there may be an air bubble.
434 425	9.1.10. Once the suite alignment (valte as sheet, is as malete, use the same registion due a decum
435	8.1.10. Once the auto alignment/voltage check is complete, use the camera position drop down
430	flucting and (an elegening
437	nusning and/or cleaning.
420	9.1.11. Following OC the system will display (ready for measurements)
459	8. 1. 11. Following QC the system will display Teady for measurements .
440	P. 2. Determining EV size and concentration by Nanonarticle Tracking Analysis
441 442	o.2. Determining by size and concentration by Nanoparticle fracking Analysis
442	NOTE: A detailed description for EV quantification using NTA is described also where <sup>13</sup>
445	NOTE. A detailed description for EV quantification using NTA is described elsewhere .
444	8.2.1 Prime the flow cell with PRS. Onen the 'Pump/temp' tab and under 'nump' click 'run' for
445	8.2.1. Finne the now cell with FBS. Open the Fullpytemp tab and under pump click run for
440	NOTE: You may see particles in the chamber but these can be cleared by pushing 10 mL of DBS
447 119	through the leading port
440 440	unough the loading port.
449	9.2.2. Fills 10 mL gwings with DBS and load into the shamber with no signification
43U 454	o.2.2. Fin a 10 mL synnge with PBS and load into the champer with no air pubbles.
451 452	9.2.2. Create a protocol for the device to run that will recover coulting a sitistic of the large
452	o.2.5. Create a protocol for the device to run that will measure multiple positions of the laser
453	and average the particles per frame.

454	
455	8.2.4. Check the particle count is less than 5 (as close to 0 as possible) before proceeding $-$
456	flush with more PBS if necessary.
457	
458	8.2.5. Prior to dilution, mix the EV sample by pipetting.
459	
460	8.2.6. Dilute your sample 1:1000 in PBS and mix my pipetting. Fill a 1 mL syringe with your
461	sample and load into the chamber with no air bubbles.
462	
463	8.2.7. Check that the particle count is within the acceptable range (the bar above your count
464	value should be in the green region, or close to it). If not, adjust your sample dilution
465	accordingly. In between samples and sample dilutions load 10 mL PBS into the front of the
466	machine to clear the chamber, then load 1 mL of your diluted sample.
467	
468	NOTE: Each sample will independent dilution based on the concentration of the sample. The
469	particle count of the device should be between 50 - 200 particles per frame for accurate
470	measurements.
471	
472	8.2.8. Go to the 'measurement' tab in the software.
473	
474	8.2.9. Click the 'Run video acquisition' button.
475	
476	8.2.10. Enter a sample name and select a destination folder to save the measurement.
477	
478	8.3. Create an EV standard operating procedure (SOP)
479	
480	8.3.1. Create Save and Load and EV SOP – that will measure particle number and size at a
481	shutter speed of 100 and camera sensitivity of 80, 11 camera positions for 2 cycles – NOTE:
482	unless your sample has special requirements, there is no need to change these settingsSOP
483	
484	8.3.2 Enter the dilution of your sample and add any other notes you wish to add
485	Sister the under of your sumple and add any other notes you wish to dud.
486	8.3.3 Click 'OK' and the software will automatically start recording
487	NOTE: Do not touch the machine or nearby countertons during this time as vibrations will
482	influence the final readings
400 189	
<u>4</u> 90	8.3.4. Once finished, the software will automatically load a non-up table showing avorage
490	narticle counts and sizes for each camera position
491 497	
-72 /102	8.3.5 Camera positions with statistically unusual readings will automatically be evoluded if
101	vou would like to manually evolute any camera positions (or re-include evoluted energing)
434 105	reason) click the check hav to the left of the cample details
433	reasony then the theth box to the left of the sample details.
490 407	9.2.6 Click (continue) and the coftware will create and once a DDE of your provide codether inc
47/	o.j.o. Chek continue and the solutione will create and open a PDF of your sample and the size

#### 498 and concentration results.

499

501

500 8.4. Statistical Analysis

8.4.1. NTA data was analyzed by one-way or two-way ANOVA with post-hoc Tukey correction.
Data are plotted as group means ± standard deviation. A P value of <0.05 was considered</li>
significant.

505

### 506**REPRESENTATIVE RESULTS:**

507 We determined the quantity of EVs isolated from human gluteal adipocytes following the 508 described protocol. We calculated the size and concentration of adipocyte-derived EVs using NTA (Figure 1 A,B). We utilized sham-media controls, which were equal volumes of media that 509 510 had not been in contact with cells, but cultured and subject to the isolation procedure 511 described above. We measured the adipocyte-derived EV concentration following the initial 512 isolation and after washing the isolated adipocyte EVs in PBS (Figure 1 A,B) and plotted the 513 group means  $\pm$  standard deviation (SD), which was analyzed by a two-way ANOVA with post-514 hoc Tukey correction.

515

The concentration of adipocyte-derived EVs determined by NTA from the 1<sup>st</sup> isolation ranged 516 from  $6.10 \times 10^6$  to  $2.70 \times 10^7$  with a median of  $2.60 \times 10^7$  EVs/mL (Figure 1 A,B). Following a PBS 517 wash there were significantly fewer adipocytes derived EVs per sample (Figure 1 A,B) (P<0.001), 518 which ranged from 5.00 x  $10^5$  to 4.30 x  $10^6$  with a median of 2.70 x  $10^6$  EVs/mL. The sham-519 520 media controls contained no EVs as determined by NTA (Figure 1 A,B). The modal size of EVs 521 from the first isolation was 125 nm and 105 nm following a PBS wash (Figure 1 A,B). The described protocol was further applied to abdominal and gluteal derived-adipocytes from larger 522 T175 cm<sup>2</sup> flasks. These gluteal EV samples derived from T175 cm<sup>2</sup> flasks ranged in concentration 523 from 3.60 x  $10^7$  to 7.50 x  $10^7$ /mL with a median of 5.40 x  $10^7$  EVs/mL. Abdominal adipocyte 524 derived EVs from T175 cm<sup>2</sup> flasks ranged in concentration from  $6.30 \times 10^7$  to  $8.60 \times 10^7$ /mL with 525 a median of 7.60 x  $10^7$  EVs/mL (Figure 1 C,D). The modal size of EVs derived from the T175 cm<sup>2</sup> 526 flasks was 115 nm for gluteal EVs and 125 nm abdominal EVs. We confirmed the presence of 527 528 EV-protein in gluteal and abdominal derived EVs by immunoblotting for tumor susceptibility 529 gene 101 (TSG101) and found that abdominal and gluteal adipocyte cell pellets and abdominal and gluteal adipocyte-derived EVs were positive for TSG101, whereas as sham-control media, 530 531 which had not been in contact with cell was negative (Figure 1E).

532

# 533 **FIGURE AND TABLE LEGENDS:**

534 Figure 1: Size and distribution profile of adipocyte-derived EVs from cell culture media and determination of EV-protein TSG101. Total EV concentrations and size and concentration 535 distribution profiles as determined by Nanoparticle Tracking Analysis (NTA) from the 1<sup>st</sup> 536 537 isolation (N=5) and following washing with PBS (N=6). (C) Total concentrations and (D) size and 538 concentration distribution profiles determined by NTA for abdominal and gluteal derived EVs from T175cm2 flasks (N=4 per group). (E) Western blot of gluteal and abdominal derived EVs for 539 540 TSG101. Cell pellets and sham-media were used as positive and negative controls respectively. 541 Data are group means ± standard deviation (SD). A one-way or two-way ANOVA with post-hoc

542 Tukey correction. \*\*\* P<0.001

543

#### 544 **DISCUSSION:**

545 We demonstrate a protocol for the isolation of gluteal and abdominal adjpocyte-derived EVs from cell culture supernatants and determined their size and concentration by NTA<sup>7,14,15</sup>. We 546 547 show that cultured human adipocytes produce and release EVs into the cell culture media, 548 which can be subsequently isolated using filtration and ultracentrifugation. We determined the 549 size and concentration profile of isolated adjpocyte derived EVs and show that 550 ultracentrifugation likely co-isolated contaminants from the cell culture media and that washing 551 the isolated EV pellets in PBS significantly lowers their concentration in a second NTA 552 measurement. We further determined the purity of the isolated gluteal and abdominal derived EVs by western blotting for TSG101 an EV-marker. Gluteal and abdominal derived EV 553 554 preparations were positive for TSG101 but importantly this was absent in control-media that 555 was not exposed to cells. The presented experiments used human adjpocytes as the parent cell 556 generating EVs but the described method is suitable for other cell types including, endothelial 557 cells, vascular smooth muscle, skeletal muscle, immune cells and for the isolation of EVs from 558 patient platelet poor plasma or serum.

559

560 Adjpocyte derived EVs are elevated in metabolic diseases and determining alterations in the size and number of adipocyte EVs in vivo is complex because biological fluids such as blood 561 contain EVs from a number of cell sources that are also implicated in the pathogenesis of 562 metabolic disease, including EVs from endothelial cells, skeletal muscle, erythrocytes and 563 564 immune cells. The method described here allows determination of human adipocyte EVs, which 565 may provide a useful model for mechanistic studies investigating the factors that lead to EV 566 biogenesis in adipocytes, which is currently unknown. Importantly, determining adipocyte EV 567 biogenesis and how loading of particular RNAs, proteins and metabolites is orchestrated in adipocyte EVs may reveal novel therapeutic opportunities to perturb pathogenic adipocyte EV 568 signaling in metabolic dysfunction. Detailed studies will provide a better understanding of how 569 570 EV size, number, biogenesis pathway and EV-cargo (RNA, proteins and metabolites) are altered 571 in response to disease or stimuli such as perturbations in oxygen, glucose, lipids and insulin. 572 Information on the role of environmental factors on adipocyte EV signaling in metabolic disease 573 and how adipocyte-derived EVs contribute towards adipose tissue inflammation may uncover 574 novel therapeutic targets in metabolic disease.

- 575
- 576 Limitations
- 577 in vitro generation of adipocyte derived EVs

578 The use of human preadipocytes in vitro provides a model system to study the release and 579 generation of adipocyte-derived EVs following in vitro adipocyte differentiation but there are a number of limitations. In particular, in vitro derived adipocyte EVs are likely to differ from 580 adipose-derived EVs retrieved from bio fluids, such as plasma<sup>14</sup> in their size, concentration, EV-581 582 protein,-RNA, -metabolites and function. These EV differences could be influenced by other non-adipocyte cells that are resident in adipose tissue in vivo, such as adipose tissue derived 583 584 stem cells, endothelial cells and macrophages, which are intimately linked to adipose tissue 585 physiology and have shown roles in adipose tissue pathology, including adipose tissue

586 inflammation.

587

It should be noted that the two week in vitro differentiation protocol described here may not be sufficient to generate fully mature adipocytes equivalent to those seen in vivo; in vitro differentiated adipocytes grown in a two-dimensional format display a different morphology to in vivo cells and do not develop unilocular lipid droplets..Furthermore, the preadipocytes described in this protocol are obtained from the adipose stromal-vascular fraction and we have not assessed the contribution to EV pool from other cell types which were not completely eliminated during the cell isolation.

595

596 The loss of important cell to cell interactions of adipocytes with other non-adipocytes in 597 adipose tissue may influence adipocyte EV generation, release, ,EV-protein and EV-RNA from 598 adipocytes and adipose tissue derived stem cells <sup>16</sup>. However, an assessment of how in vitro 599 derived adipocyte EVs differ from those produced in vivo has not been undertaken 600 exhaustively.

601

602 Primary tissue biopsies contain blood and therefore the derived cell cultures may contain 603 erythrocytes and erythrocyte derived EVs irrespective of the multiple washes and media 604 changes highlighted in our protocol. An additional red blood cell lysis step following isolation of 605 the stromal-vascular fraction may be necessary to eliminate the effects of erythrocytes on 606 adipocytes. This is important because erythrocyte derived EVs can impact the cellular function 607 of other cells <sup>17</sup> and erythrocyte derived EVs are elevated in the presence of oxidative stress <sup>18</sup> and in patients with metabolic syndrome <sup>19,20</sup>. Therefore adipose tissue derived from metabolic 608 609 disease patients may contain elevated levels of erythrocyte derived EVs, which may influence 610 the in vitro phenotype of adipocytes.

- 611
- 612 Elimination of FBS

613 Our described protocol utilized FBS in the growth media during adipogenic differentiation but 614 subsequently the adipocytes were subject to multiple media changes before the final media 615 collection for the isolation of adipocyte derived EVs. Therefore, we assumed the overall risk for 616 contamination of FBS derived EVs in ours EVs preparations to be low and subsequently 617 confirmed that residual EVs were not present in the cell culture media by western blotting for 618 TSG101. The isolation of cell cultured EVs from cell sources that require FBS must use EV-619 depleted FBS or deplete bovine-EVs through ultra-centrifugation to prevent bovine-EVs confounding adipocyte EV concentrations and analysis of adipocyte EV cargo. Depletion of 620 serum from adipocytes is known to alter their cellular responses <sup>21</sup> and therefore investigation 621 must ensure that serum depletion or EV-depletion from serum renders their adipocyte cultures 622 623 truly representative of adipocyte biology.

624

625 Technical limitation of EV isolation using filtration and ultracentrifugation

626 We describe a method of ultracentrifugation with single use plastic tubes that require sealing

627 prior to ultracentrifugation for EV isolations. We acknowledge that these single use sealed

628 tubes may not be an economical option for many individuals and suggest exploration of similar

629 tubes, which do not require sealing and are reusable. However, investigators must ensure that

washing of reusable tubes is adequate and does not lead to progressive accumulation ofprotein, lipid and RNA contaminants overtime, which may impact downstream investigations of

632 EV associated cargo or impact on cellular function studies.

633

634 The filtration and ultracentrifugation protocol described here has been used for numerous 635 years and multiple studies have highlighted the short fallings of this method, including the non-636 specific isolations of contaminating cellular components such as cellular mitochondria, the 637 presence of nuclear fragments and constituents of the cell membrane. Furthermore, the 638 method described here will co-isolate lipoproteins produced by adjpocytes or those present in 639 EV-depleted FBS. The method here may be further developed by the use of density 640 ultracentrifugation and size exclusion chromatography (SEC) to eliminate contaminating soluble 641 proteins and some lipoproteins. Coupled with PBS washing of the isolated EVs and SEC the co-642 isolated contaminants can be limited but not completely eliminated. Therefore, users should 643 ensure the inclusion of appropriate controls, including a sham-media that has not been in 644 contact with cells to account for soluble proteins and lipoproteins in the culture media and an 645 EV-depleted supernatant control to demonstrate the successful isolation of EVs from 646 conditioned media that still contains soluble proteins and lipoproteins.

647

648 The isolation of EVs using filtration and ultracentrifugation relies on the operator ensuring 649 undue pressure is not applied to the cell culture supernatants whilst it is passed through the 650 bore of the filter or the bore of the needle/syringe. Application of undue force during this stage of the described protocol may rupture EVs, influence the final EVs concentrations and generate 651 652 free RNA, proteins and metabolites, which were once encased in EVs. We have described a 653 method here, which doesn't require the syringe barrel and therefore the application of force to 654 the EVs in conditioned media as they pass through the filter or needle into their collection 655 reservoirs and ultracentrifugation tubes. Nonetheless, further care must be undertaken when 656 resuspending the EV pellet in PBS. Only a brief vortex must be used, as vigorous vortexing may 657 disrupt the EV membranes.

658

659 Following ultracentrifugation operators must be careful with the ultracentrifugation tubes as 660 not to disturb the EV pellet. This can be achieved by handling the tubes carefully and moving 661 them slowly between the ultracentrifugation rotor and the tube rack. Further care must be 662 taken when piercing a hole in the top of ultracentrifugation tube to aspirate the EV-depleted 663 supernatants. Inserting the needle into the top of the tube and aspirating the supernatants 664 quickly will create a vacuum in the syringe barrel, which can violently force the supernatant 665 back into the ultracentrifugation tube and disrupt the EV pellet. After cutting the ultracentrifugation tube to pour off the remaining supernatant, care must be taken because the 666 667 EV pellet may become loose and pouring will discard the EV pellet. Alternatively, a syringe and needle can be used to slowly remove the remaining supernatant without pouring or inverting 668 669 the tube.

670

Filtration and ultracentrifugation of supernatants for the isolation of EVs is a useful and efficient method. But it is liable to the co-isolation of lipoproteins and soluble proteins. These can be mitigated by washing the EVs with PBS (as described) but this will not eliminate all

contaminants. Soluble proteins can be eluted from the EV fraction by utilizing SEC), however 674 675 this method does not distinguish between lipoproteins and EVs. SEC-elutions that contains EVs 676 can be combined with ultracentrifugation to pellet EVs. Filtration and differential 677 ultracentrifugation is a preferred method of EV isolation over precipitation techniques, which 678 use polyethylene glycol because these precipitation methods co-isolate large quantities of 679 soluble proteins and lipoproteins in cell culture supernatants and other biological fluids. 680 Ultracentrifugation is likely to remain the most accessible form of EV isolation for many 681 because most laboratories are equipped with an ultracentrifuge, therefore mitigating initial 682 startup costs. But for many ultracentrifugation for EV isolation is hindered by the volume of 683 ultracentrifugation tubes and the starting volume of material. Several 100 mL's of culture 684 supernatants may be needed to produce sufficient EV quantity for downstream proteomics or 685 RNA-sequencing. However, it is likely that ultra-centrifugation techniques for EV isolation will 686 be accompanied by other techniques such as SEC and immuno-affinity capture using 687 tetraspanins CD9, CD63 and CD81 to improve the purity of isolated EVs. Other techniques such 688 as commercially available precipitation solutions and flow cytometry may be of some use in 689 specific investigations.

- 690
- 691 Purity of EV preparations

We confirmed the isolation of adipocyte derived EVs by western blotting for TSG101 but this single western blot falls short of the guidelines published by the international society for extracellular vesicles (ISEV). Further characterization of these adipocyte derived EVs would be ideal using tetraspanins CD9, CD63 and CD81 to identify exosomes and markers of cellular contamination such as histone H3, albumin and apolipoprotein A1.

697

698 The protocol presented here allows the isolation of EVs from cell culture supernatants from a 699 range of cell sources including adipocytes for determination of EV size, concentration, EV-700 markers by western blot and utility in omics based technologies such as proteomics and RNA-701 sequencing.

702

### 703 **ACKNOWLEDGMENTS**:

704 N.A. and R.C. acknowledge support by research grants from the British Heart Foundation the 705 Centre of Research Excellence, Oxford (N.A. and R.C.; RE/13/1/30181 and RE/18/3/34214), 706 British Heart Foundation Project Grant (N.A. and R.C.; PG/18/53/33895), the Tripartite 707 Immunometabolism Consortium, Novo Nordisk Foundation (NNF15CC0018486), the National 708 Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), Nuffield 709 Benefaction for Medicine and the Wellcome Institutional Strategic Support Fund (ISSF). The 710 views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or 711 the Department of Health.

- 712
- 713 **DISCLOSURES:**
- 714 The authors have nothing to disclose
- 715
- 716 **REFERENCES**:

717 1 Théry, C. et al. Minimal information for studies of extracellular vesicles 2018

(MISEV2018): a position statement of the International Society for Extracellular Vesicles and
update of the MISEV2014 guidelines. *Journal of Extracellular Vesicles*. 7 (1), 1535750, (2018).

Akbar, N. *et al.* Endothelium-derived extracellular vesicles promote splenic monocyte
 mobilization in myocardial infarction. *JCI Insight.* 2 (17), (2017).

Xiao, Y. *et al.* Extracellular vesicles in type 2 diabetes mellitus: key roles in pathogenesis,
 complications, and therapy. *Journal of Extracellular Vesicles* 8, 1625677 (2019).

Akbar, N., Azzimato, V., Choudhury, R. P. & Aouadi, M. Extracellular vesicles in metabolic
disease. *Diabetologia*. 62 (12), 2179-2187, (2019).

5 Kobayashi, Y. *et al.* Circulating extracellular vesicles are associated with lipid and insulin metabolism. *The American Journal of Physiology-Endocrinology and Metabolism.* **315** (4), E574-E582, (2018).

Eguchi, A. *et al.* Circulating adipocyte-derived extracellular vesicles are novel markers of
metabolic stress. *Journal of Molecular Medicine (Berlin, Germany).* 94 (11), 1241-1253, (2016).

731 7 Crewe, C. *et al.* An Endothelial-to-Adipocyte Extracellular Vesicle Axis Governed by 732 Metabolic State. *Cell.* **175** (3), 695-708 e613, (2018).

733 8 Flaherty, S. E., 3rd *et al.* A lipase-independent pathway of lipid release and immune 734 modulation by adipocytes. *Science.* **363** (6430), 989-993, (2019).

Deng, Z. B. *et al.* Adipose tissue exosome-like vesicles mediate activation of
macrophage-induced insulin resistance. *Diabetes.* 58 (11), 2498-2505, (2009).

Kranendonk, M. E. *et al.* Human adipocyte extracellular vesicles in reciprocal signaling
between adipocytes and macrophages. *Obesity (Silver Spring).* 22 (5), 1296-1308, (2014).

Song, M. *et al.* Adipocyte-Derived Exosomes Carrying Sonic Hedgehog Mediate M1
Macrophage Polarization-Induced Insulin Resistance via Ptch and PI3K Pathways. *Cellular Physiology and Biochemistry.* 48 (4), 1416-1432, (2018).

Ramirez, M. I. *et al.* Technical challenges of working with extracellular vesicles. *Nanoscale.* **10** (3), 881-906, (2018).

74413Mehdiani, A. et al. An innovative method for exosome quantification and size745measurement. Journal of Visual Experiments. 10.3791/50974 (95), 50974, (2015).

746 14 Connolly, K. D. *et al.* Evidence for Adipocyte-Derived Extracellular Vesicles in the Human
747 Circulation. *Endocrinology.* **159** (9), 3259-3267, (2018).

Camino, T. *et al.* Vesicles Shed by Pathological Murine Adipocytes Spread Pathology:
Characterization and Functional Role of Insulin Resistant/Hypertrophied Adiposomes. *International Journal of Molecular Sciences.* **21** (6), 2252, (2020).

751 16 Zhu, Y. *et al.* Extracellular vesicles derived from human adipose-derived stem cells
752 promote the exogenous angiogenesis of fat grafts via the let-7/AGO1/VEGF signalling pathway.
753 Scientific Reports. 10 (1), 5313, (2020).

75417Sadallah, S., Eken, C. & Schifferli, J. A. Erythrocyte-derived ectosomes have755immunosuppressive properties. Journal of Leukocyte Biology. 84 (5), 1316-1325, (2008).

Sudnitsyna, J. *et al.* Microvesicle Formation Induced by Oxidative Stress in Human
Frythrocytes. *Antioxidants (Basel).* 9 (10), (2020).

Helal, O. *et al.* Increased levels of microparticles originating from endothelial cells,
platelets and erythrocytes in subjects with metabolic syndrome: relationship with oxidative
stress. *Nutrition, Metabolism and Cardiovascular Diseases.* 21 (9), 665-671, (2011).

761 20 Agouni, A. et al. Endothelial dysfunction caused by circulating microparticles from

patients with metabolic syndrome. *The American Journal of Pathology*.**173** (4), 1210-1219,(2008).

764 21 Park, J., Park, J., Nahm, S. S., Choi, I. & Kim, J. Identification of anti-adipogenic proteins

in adult bovine serum suppressing 3T3-L1 preadipocyte differentiation. BMB Reports. 46 (12),

766 582-587, (2013).

767



Abdominal adipocyte cell pellet Gluteal adipocyte cell pellet Abdominal adipocyte EV Б< adipocyte media Gluteal L Sham

44 kDa